Abstract
As of 28 October 2020, there are over 44 000 000 confirmed COVID-19 infections and over 1 000 000 deaths worldwide, including 945 367 infections and 45 765 deaths in the UK. Acute respiratory distress syndrome occurs in 50% of patients with secondary haemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome characterised by a surge of cytokines, including interleukin 6 (IL-6). Here we describe the case of the first patient with severe COVID-19 pneumonia successfully treated with tocilizumab, a humanised monoclonal antibody against the IL-6 receptor, in the UK. Early treatment (after 7-10 days from the onset of symptoms) with tocilizumab could (1) reduce the risk of requiring non-invasive or invasive ventilation; (2) offer a chance of survival to people who are not fit for escalation or have refused to be ventilated; and (3) potentially increase the chance of survival in some patients who are already ventilated but fail to improve with supportive treatment.
Author supplied keywords
Cite
CITATION STYLE
Gentile, G., Davies, R., Manfreda, V. M., & Ul Abideen, Z. (2021). Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab. BMJ Case Reports, 14(1). https://doi.org/10.1136/bcr-2020-238210
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.